cor2ed
engage checkpoint medical linkedin twitter
bg

Pituitary Masterclass 2019

Pituitary Masterclass 2019

Pituitary Masterclass 2019

Friday 18th – Saturday 19th October 2019 San Raffaele Congress Centre, Milan, Italy

Pituitary Masterclass 2019

preview next

time Video | open 5 min

download resources

THERE ARE NO DOWNLOADS FOR THIS PROGRAMME

I agree that this educational programme:

Was valuable to me:

1/3

The Programme

An educational programme with extensive opportunities for audience participation, sharing and learning through experiences and asking questions to peers and experts.

The Masterclass will start at 12:00 on Friday 18th October and finish at 15:45 on Saturday 19th October. There will be a dinner for all attendees on Friday 18th October.

The detailed programme can be found here: Pituitary Masterclass

The programme will cover the following areas:

  • Opening Lecture: Neurosurgery

Plenary Sessions:

  • Acromegaly
  • PTCOE (Pituitary Tumours Centre of Excellence)
  • Cushing’s Disease
  • Novel Treatments in pituitary disease
  • Special clinical issues in pituitary disease

Meet the Expert Sessions:

  • Management of pituitary adenomas
  • Outcomes in pituitary adenomas
  • Patient session: Acromegaly FAQs

Breakout sessions:

  • Aggressive pituitary tumours
  • Diabetes insipidus
  • Pituitary imaging

Disclosures

SCIENTIFIC COMMITTEE

  • Prof Andrea Giustina has the following relevant financial information to disclose: Grants/Consultancy (Abiogen, Astellas, Ipsen, Novartis, Pfizer)
  • Prof Felipe Casanueva has the following relevant financial information to disclose: Grants/Consultancy (Ipsen)
  • Prof Philippe Chanson has the following relevant financial information to disclose: Grants (Ipsen, Novartis, Novo-Nordisk, Pfizer, Tiburio)
  • Prof Maria Fleseriu has the following relevant financial information to disclose: Grants/Consultancy (Chiasma, Ionis, Ipsen, Millendo, Novartis, Novo-Nordisk, Pfizer, Strongbridge)
  • Prof Stephan Petersenn has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novartis, Pfizer)

FACULTY

  • Prof Pietro Mortini does not have any relevant financial relationship to disclose
  • Prof Anton Luger has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novo-Nordisk, Novartis, Pfizer, Sandoz)
  • Prof Marco Losa does not have any relevant financial relationship to disclose
  • Prof Stefano Frara has the following relevant financial information to disclose: Grants/Consultancy (Ipsen)
  • Prof Nienke Biermasz does not have any relevant financial relationship to disclose
  • Dr Francesco Tecilazich does not have any relevant financial relationship to disclose
  • Dr Anna Formenti has the following relevant financial information to disclose: Grants/Consultancy (Abiogen, Sandoz)
  • Prof Luca Persani has the following relevant financial information to disclose: Grants/Consultancy (Merck-Serono, Sandoz)
  • Prof Monika Marazuela does not have any relevant financial relationship to disclose
  • Prof Martin Reincke does not have any relevant financial relationship to disclose
  • Prof Ezio Ghigo does not have any relevant financial relationship to disclose
  • Prof AnaMaria Colao has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novartis, Pfizer)
  • Prof Thierry Brue has the following relevant financial information to disclose: Grants/Consultancy (Ipsen, Novartis, Pfizer)
  • Prof Laura DeMarinis does not have any relevant financial relationship to disclose
  • Dr Eugene Resmini does not have any relevant financial relationship to disclose
  • Prof Prof Niki Karavitaki has the following relevant financial information to disclose: Grants/Consultancy (Novartis, Pfizer)
  • Prof Paolo Loli does not have any relevant financial relationship to disclose
  • Dr Raphael Souillard-Scemama does not have any relevant financial relationship to disclose

PLANNING COMMITTEE

  • Iain Murdoch of COR2ED has the following relevant financial information to disclose: Shareholder (AstraZeneca)

This programme is supported by an Independent Educational Grant from Ipsen

Other programmes of interest

preview next